SuperworthKALA BIO price to sales ratio KALA
Market value divided by revenue over the last twelve months, since 2020.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 8.9×
- Jul 2023
- 7-year median
- 17.3×
- 7-year range
- 1.0× to 199×
- Peer median
- 1.4×
KALA BIO's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.
It was last meaningful in Jul 2023, at 8.9×.
On the days it had one over the last 7 years, its median was 17.3×, from 1.0× in Dec 2022 to 199× in Feb 2021.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2023 | 8.9× | 3.0× | 10.0× |
| 2022 | 10.1× | 1.0× | 20.7× |
| 2021 | 13.6× | 13.6× | 199× |
| 2020 | 143× | 64.8× | 199× |
Against its peers
Companies in Healthcare nearest KALA BIO's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| KALAKALA BIO | n/m |
| OXBROXBRIDGE RE HOLDINGS | 2.8× |
| EDUCEducational Development | 0.4× |
| GTIMGood Times Restaurants | 0.1× |
| MDRRMedalist Diversified | 1.6× |
| BCGBinah Capital | 0.1× |
| VIPVulcan Infrastructure & Power | 0.4× |
| MXCMexco Energy | 3.0× |
| CKXCKX Lands | 31.0× |
| MSGMMotorsport Games | 1.5× |
| ATCHAtlasClear | 1.2× |
| Peer median | 1.4× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on KALA BIO
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.